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Background: Absence of interlobar collateral ventilation is key to successful 
endobronchial valve treatment in patients with severe emphysema and can be 
functionally assessed using the Chartis® measurement. Chartis has been 
validated during spontaneous breathing, undergoing procedural sedation (PS), 
but can also be performed under general anesthesia (GA). Performing Chartis 
under PS is often challenging because of coughing, mucus secretion and 
difficulties in maintaining an adequate level of sedation. The study objective was 
to investigate whether there is a difference in Chartis measurement outcomes 
between PS and GA. 
Methods: In this prospective study patients underwent Chartis measurements 
under both PS and GA. Study outcomes were Chartis measurement duration, 
number of measurements, feasibility and success rate. 
Results: We included 30 patients with severe emphysema (mean age 62 years 
and median FEV1 29% of pred.). Chartis measurement duration was significantly 
longer under PS than under GA (mean 20.3±4.2 minutes versus 15.1±4.4, 
P<0.001). There was no difference in the number of measurements performed 
(median 2 (range 1-3) for PS versus 1 (1-3) for GA, P=1.00). Chartis 
measurement was more feasible during GA (median sum of all feasibility scores: 
12 (range 6-26) for PS versus 7 (5-13) for GA, P<0.001), with no statistical 
difference in success rate: 77% of cases for PS versus 97% under GA, P=0.07. 
Conclusion: This study shows that Chartis measurement under general 
anesthesia is faster and more feasible to perform compared to procedural 
sedation, without affecting measurement outcomes. 
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Registration: Clinicaltrials.gov; No. NCT03205826; URL: www.clinicaltrials.gov 
Introduction: 
Bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV) is 
an effective and safe treatment for selected patients with severe emphysema1–4. 
To achieve EBV treatment benefit, interlobar collateral ventilation (CV) must be 
absent, as the presence of CV prevents the desired atelectasis of the target 
lobe5. The presence of CV can be assessed using indirect measurement 
techniques such as quantitative computed tomography fissure analysis and 
hyperpolarized gas magnetic resonance imaging or direct techniques such as 
collateral flow measurement during bronchoscopic assessment with the Chartis 
System® (Pulmonx Inc., Redwood City, CA, USA)6,7. The Chartis system consists 
of a catheter which is designed to be advanced through the working channel of a 
flexible bronchoscope and uses an inflatable balloon at the tip of the catheter to 
selectively occlude the entrance of a lung lobe (see figure 1). The system 
measures flow from the occluded lobe and calculates the resistance to airflow 
through collateral channels and quantifies the amount of CV within a specific 
lobe8. 
In our BLVR treatment expert center, all patients scheduled for EBV treatment 
undergo a Chartis measurement to determine CV status. Chartis measurement 
was originally validated in patients breathing spontaneously undergoing 
procedural sedation (PS)9. However, performing a Chartis measurement under 
PS can be very challenging because of problems with catheter placement caused 
by coughing reflexes of the patient, mucus secretions that can occlude the 
catheter, swelling of the airway mucosa causing challenging measurements and 
difficulties in maintaining a sufficient level of sedation. Although in several recent 
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EBV trials as well as in our ongoing regular treatment program BREATH-NL 
(NCT02815683) we have performed Chartis measurement under general 
anesthesia (GA), the measurement has not yet been validated under GA2–4. We 
recently published a retrospective analysis on this topic, suggesting advantages 
of Chartis measurement under GA with shorter procedure times and fewer 
measurements necessary, without a difference in target lobe volume reduction 
after EBV treatment10. The objective of this study was to prospectively compare 
Chartis measurement under PS versus GA. We hypothesized that Chartis 
measurement under GA would result in faster procedures with higher physician 
assessed feasibility and with similar diagnostic outcome. 
Methods: 
Study design and participants: 
We performed a single center prospective study in which we included patients 
with severe emphysema (NCT03205826), who met the inclusion criteria for EBV 
treatment5. For safety reasons, patients that met the following criteria were 
excluded from participation: forced expiratory volume in one second (FEV1)<20% 
of predicted, residual volume/total lung capacity (RV/TLC) ratio >70%, 
pCO2>6.5 kPa at baseline at room air, right ventricular systolic 
pressure>40mmHg on echocardiogram, 6 minute walking distance <200 meter, 
known intolerance to lidocaine or any medical reason that warranted a short 
procedure. 
The study was approved by the University Medical Center Groningen medical 





CV status was evaluated in all patients using Chartis measurement under PS, 
followed by Chartis measurement under GA in the same procedure. The same 
lobes were assessed under PS and under GA. In all patients the measurements 
were performed in the target lobe for EBV treatment and when indicated the 
measurements were also performed in the ipsilateral or secondary target lobes. 
Chartis measurement was terminated when either absence of collateral 
ventilation was confirmed by an airway flow gradually approaching zero (with 
airway resistance > 10cm H2O x ml/s for PS) in combination with immediate 
return of airway flow upon release of the balloon catheter (ruling out catheter 
obstruction), or when the presence of collateral ventilation was confirmed with 
the observation of a continuous, non-decreasing, expiratory airway flow during 
>6 minutes or totaling > 1 liter11,12. All Chartis measurements were performed 
by one interventional pulmonologist, who had previous experience with this 
measurement under PS and GA (DJS). 
Anesthetic management:  
Anesthetic management consisted of two phases: PS and GA. Patient monitoring 
during both phases consisted of 3-lead ECG, SpO2, non-invasive blood pressure 
monitoring, end-tidal CO2 measurement and electroencephalography based 
depth of sedation monitoring using a BIS monitor (BIS VISTA®, Medtronic, 
Dublin, Ireland). 
PS was induced using infusions of propofol and remifentanil. Propofol (20mg/ml) 
was administered by effect-site (Ce) targeted-controlled infusion (TCI) using the 
Schnider model with a starting target Ce concentration of 1 µg/ml13. Remifentanil 
(50 µg/ml) was administered by effect-site (Ce) TCI using the Minto model 
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starting at an initial target Ce of 1.0 ng/ml14. Sedation depth was controlled 
primarily by adjusting the propofol target Ce concentration while the target 
remifentanil Ce was reduced on indication but rarely increased above 1.0 ng/ml. 
Lidocaine 10mg/ml was applied topically to the larynx by the interventional 
pulmonologist. Sedation was maintained in the time period between the PS 
phase and the GA phase. 
In order to pre-oxygenate the lungs adequately for the induction of GA, patients 
were administered 100% O2 through a tight fitting face mask while still under PS. 
After pre-oxygenation Ce-propofol and Ce-remifentanil were increased to induce 
GA, rocuronium-bromide 0.3-0.6 mg/kg was administered and endotracheal 
intubation was performed by the attending anesthesiologist using a cuffed 
Shiley™ Hi-contour Oral/Nasal Tracheal Tube (Covidien™, Mansfield, USA) with 
an internal diameter of 9mm. Thereafter GA was maintained with TCI-propofol 
and remifentanil and the patients lungs were mechanically ventilated. The 
primary ventilator settings were: volume controlled ventilation mode, fraction of 
inspired oxygen 50%, positive end-expiratory pressure 3cm H20, tidal volumes of 
4 to 6ml/kg, respiratory rate 10/min and an inspiratory:expiratory ratio of 1:3 to 
1:4. The adjustment of these settings, to ensure patient-safety, was left to the 
discretion of the attending anesthesiologist. 
Outcome measures: 
The primary outcome measure was the difference in duration of Chartis 
measurement between the sedation and GA. Secondary outcome measures were 
the time until the patient was sufficiently sedated to undergo Chartis 
measurement, success rate of Chartis measurement, number of measurements 
performed and qualitative feasibility assessment between the two anesthesia 
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methods. The duration of the Chartis measurement was defined as the time 
between the start of the applicable anesthesia phase (PS or GA) and the 
withdrawal of the Chartis catheter from the bronchoscope after Chartis 
measurement. Start of PS phase was defined as the start of propofol or 
remifentanil. Start of the GA phase was defined as the increase of propofol and 
remifentanil dosage for induction of GA. The time until the patient was 
sufficiently sedated to undergo Chartis was defined as the time between start of 
the PS or GA phases and the first advancement of the Chartis catheter through 
the bronchoscope. Measurements were considered successful when collateral 
ventilation status was classified as either positive or negative. A single 
measurement was defined as the data collected between initiation and 
termination of the measurement on the Chartis console. Chartis measurement 
was only performed once per lobe per patient, unless a measurement was 
considered unsuccessful. Feasibility of the measurement was scored for both PS 
as well as GA by the physician performing the measurement, using a 1-10 visual 
analog scale, with lower scores indicating better feasibility. Five sub-scores were 
scored: presence of mucus, amount of coughing, degree of airway collapse, need 
for breathing instruction (for PS only) and measurement feasibility. We 
calculated the sum of all sub-scores to assess overall feasibility. 
Statistical analysis: 
The sample size calculation was based on a previous study from our group, in 
which the average time of Chartis measurement was 1283±720 seconds under 
PS and 818±477 seconds under GA10. A paired samples t-test was performed 
and to reach a power of 80% with an alpha level of 0.05 and considering a 10% 
drop-out rate, a total of 30 patients were required. 
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Differences in duration, time until the patient was sufficiently sedated to undergo 
Chartis, number of measurements and feasibility score outcomes of the Chartis 
measurement between PS and GA were analysed using a paired samples t-test in 
case of normal distribution or a Wilcoxon signed rank test in case of non-normal 
distribution of data. The difference in success rate between the anesthesia 
methods was analysed using McNemar’s test. Confidence intervals for non-
normally distributed data were determined using Hodges Lehmann Estimator. 
Statistical analyses were performed using SPSS (IBM, New York, NY, USA). P-
values<0.05 were considered statistically significant. 
Results: 
In total, 31 patients signed informed consent, of which in 30 patients Chartis 
measurements were performed between April 2018 and January 2019. One 
patient was excluded from further analysis because severe bronchitis was 
observed during bronchoscopy, leading to ineligibility for EBV treatment and 
therefore no Chartis measurement was performed. The remaining thirty patients 
were included in the final analysis (23% male, mean age 63±6 years and median 
FEV1 29% (range 21-56) of predicted). Baseline characteristics can be found in 
table 1. All patients completed the study without unexpected anesthesia related 
complications or unexpected procedure related complications. 
A total of 48 Chartis measurements were performed under PS of which 19 were 
classified as CV negative and 10 were classified as CV positive. During 7 
measurements we encountered a no flow state and 12 measurements were 
classified as unknown CV status. Forty-eight measurements were performed 
under GA of which 23 were classified as CV negative and 13 were classified as CV 
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positive. During 10 measurements we encountered a no flow state and 2 
measurements were classified as unknown CV status. 
Chartis measurement took significantly longer under PS than under GA. In 
addition, with the patient under PS, it took significantly longer before the patient 
was sufficiently sedated to undergo Chartis compared to GA. No significant 
difference in the number of measurements performed was observed. The success 
rate of Chartis measurement was higher under GA compared to PS, however not 
statistically significant. Chartis outcomes are provided in table 2. 
Discrepancies in CV status outcome between PS and GA were encountered in 4 
measurements. Two measurements that were classified as CV positive under PS 
were, when measured in the same lobe of the same patient, classified as CV 
negative during GA, while two other measurements were classified CV negative 
under PS and CV positive under GA. Out of these 4 patients, 3 underwent EBV 
treatment and 1 patient was not treated based on a significant contribution of 
the occluded target lobe to the overall gas exchange of the patient. In one 
patient who was classified as CV positive under PS and as CV negative under GA, 
full lobar atelectasis was observed on high resolution computed tomography scan 
(HRCT) 6 weeks after EBV treatment. In two patients, who were classified as CV 
negative under PS and as CV positive under GA, treatment did not result in lobar 
atelectasis on HRCT at 6 weeks follow-up. 
Chartis measurements were more feasible under GA compared to PS. During PS, 
mucus score, coughing score and measurement feasibility were significantly 
worse compared to GA, while airway collapse did not differ between both 
methods (table 2). 
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There was no difference in median Ce propofol during the start of Chartis 
measurement under PS versus GA. The median Ce remifentanil during the start 
of Chartis measurement was significantly lower during PS than during GA. The 
median BIS score at the time of start Chartis measurement was significantly 
higher during PS compared to GA. All patients were mechanically ventilated 
during the GA phase. The median tidal volume was 5ml/kg (3-7) and the median 
plateau pressure observed was 18 cm H20 (13-38). During PS, a mean of 294 
±55mg lidocaine was administered topically to the patients. 
Discussion: 
This first prospective study comparing Chartis measurement of CV under PS 
versus GA showed that Chartis measurement took significantly longer and was 
less feasible under PS compared to this measurement under GA. The 
performance of Chartis measurement was less feasible under PS, with more 
mucus and coughing problems. No statistical differences were found in the 
number of measurements or the measurement success rate. 
Chartis measurement is an important tool used to assess interlobar CV status 
and achieve EBV treatment success, and should ideally be performed in 
circumstances that allow for fast and effective measurement, preferably in the 
same session in which the EBV placement is performed5. 
The differences in duration and feasibility between PS and GA that we found are 
likely to be caused by more mucus production, causing catheter obstruction, or 
coughing resulting in problems with catheter positioning, as well as maintaining 
adequate sedation levels in the PS group, all causing more difficult measurement 
and interpretation of Chartis results. 
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The results of this study are in line with a retrospective analysis performed by 
our group in which longer and more frequent measurements under PS were 
observed, without a difference in target lobe volume reduction after EBV 
treatment10. The nominal success rate of Chartis measurement in this study was 
higher for GA, but this difference was not statistically significant. 
In addition, and supportive of our findings, a recently published retrospective 
analysis by Thiruvenkatarajan et al. comparing PS and GA suggests better 
interventional conditions, patient comfort and reduced anesthetic time under 
GA15. 
No direct unexpected anesthesia related complications or direct unexpected 
procedure related complications were observed in our study. Thiruvenkatarajan 
et al. describe occurrence of mild hypotension periods during EBV treatment 
under GA, in line with expected blood pressure decline after induction of GA and 
responding to vasopressor bolusses. One case of severe hypotension in the same 
study was observed which was ascribed to possible anaphylaxis and led to 
procedure termination15. Post-treatment expected complications were not 
registered for our study. In the recently published LIBERATE trial, post EBV 
treatment complications were compared between procedures performed under 
PS versus GA: chest pain occurred in 40% of patients under PS versus 18% 
under GA, pneumothorax occurred in 24% of patients under PS versus 33% 
under GA and COPD exacerbations were observed in 22% of patients after PS 
versus 18% under GA, however no statistical testing was performed to compare 
the complication rates between the anesthesia methods. In the same trial, no 
difference in FEV1 outcome after EBV treatment between the two anesthesia 
methods was found4. 
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Next to the above mentioned disadvantages, performing Chartis under PS also 
has potential advantages over GA: lower dosages of medication are necessary 
and no intubation and mechanical ventilation is required. Even though the 
performance of Chartis measurement under GA is more resource intensive, 
invasive for the patient and sometimes unavailable in BLVR centers, the use of 
GA for Chartis measurement is advocated by an expert panel on BLVR5. 
A theoretical argument against the performance of Chartis under GA is that the 
use of positive pressure ventilation might open CV channels, which would not be 
open under spontaneous breathing circumstances, leading to a false positive CV 
outcome. In the current study we did not observe any relevant differences in CV 
status outcomes between PS and GA. This observation is further supported by 
our previously published retrospective analysis in which no difference in target 
lobe volume reduction outcome between the two methods was seen after EBV 
treatment10. 
Because patients in this study received PS before conversion to GA, the time 
needed to induce GA could have hypothetically been reduced and led to 
underestimation of the time before the patient was sufficiently sedated to 
undergo Chartis measurement. With the TCI-technique used in our institution, 
however, the time needed to increase remifentanil from PS to GA levels using 
target-controlled infusion is approximately 80 seconds while the time needed to 
achieve GA levels of remifentanil when starting from 0 is approximately 90 
seconds. In other words, the sedation Ce’s of propofol and remifentanil have not 
led to a significant reduction of the time needed to induce GA while in addition 
during the induction of GA, the anesthesiologist had to wait around 3 to 4 
minutes for the neuromuscular blockade needed for tracheal intubation to take 
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effect. Finally, all feasibility outcomes were scored by only one physician, which 
might lead to an observation bias. Furthermore, we only assessed physician 
feasibility, while ideally the experience of the patients should be taken in 
consideration as well. Unfortunately this is challenging to investigate as 
procedure related amnesia occurrence will lead to recall bias. 
A strength of our study is that all Chartis measurements were performed by one 
interventional pulmonologist with experience with Chartis under both anesthesia 
techniques in one specialized treatment center, which increased standardization. 
In addition, all patients received both anesthesia techniques in a standardized 
fashion with medication dosage models and fixed ventilator settings. In our 
opinion, the fact that all patients received both PS as well as GA is a strength of 
our study. Ideally, the order in which patients undergo PS or GA first should be 
randomized, however we considered this approach unfeasible because of 
practical limitations. 
In conclusion, we suggest performing Chartis measurement under general 
anesthesia because of higher feasibility and shorter procedure times compared to 
procedural sedation, without losing diagnostic power. The results from this study 
might result in more efficient and feasible Chartis measurement in future 








Guarantor statement: J.B.A.W takes responsibility for the content of the 
manuscript, including data and analysis.  
Author contributions: J.B.A.W., K.K., J.E.H., D.J.S. and C.R.M.B undertook 
conception and design. D.J.S. and K.K. performed all Chartis measurements and 
treatments. J.B.A.W., K.K., J.E.H., I.F., D.J.S. and C.R.M.B acquired data. 
J.B.A.W., J.E.H., D.J.S. and C.R.M.B. performed analysis and interpretation. All 
authors have read, improved and approved the final manuscript. 
Role of the sponsors: Not applicable 
Acknowledgements: We would like to thank all endoscopy and anesthesiology 


















1.  Klooster K, Hacken NHT ten, Hartman JE, Kerstjens HAM, Rikxoort EM van, 
Slebos D-J. Endobronchial Valves for Emphysema without Interlobar 
Collateral Ventilation. N Engl J Med 2015;373(24):2325–2335.  
2.  Valipour A, Slebos D-J, Herth F, et al. Endobronchial Valve Therapy in 
Patients with Homogeneous Emphysema. Results from the IMPACT Study. 
Am J Respir Crit Care Med 2016;194(9):1073–1082.  
3.  Kemp S V., Slebos D-J, Kirk A, et al. A Multicenter Randomized Controlled 
Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous 
Emphysema (TRANSFORM). Am J Respir Crit Care Med 
2017;196(12):1535–1543.  
4.  Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial 
of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema 
(LIBERATE). Am J Respir Crit Care Med 2018;198(9):1151–1164.  
5.  Herth FJF, Slebos D-J, Criner GJ, Valipour A, Sciurba F, Shah PL. 
Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - 
Update 2019. Respiration 2019;1–10.  
6.  Koster TD, Slebos D-J. The fissure: interlobar collateral ventilation and 
implications for endoscopic therapy in emphysema. Int J Chron Obstruct 
Pulmon Dis 2016;11:765–73.  
7.  Marshall H, Collier GJ, Johns CS, et al. Imaging Collateral Ventilation in 
Patients With Advanced Chronic Obstructive Pulmonary Disease: Relative 
Sensitivity of 3 He and 129 Xe MRI. J Magn Reson Imaging 2018; 
8.  Mantri S, Macaraeg C, Shetty S, et al. Technical advances: measurement of 
18 
 
collateral flow in the lung with a dedicated endobronchial catheter system. 
J Bronchology Interv Pulmonol 2009;16(2):141–4.  
9.  Herth FJF, Eberhardt R, Gompelmann D, et al. Radiological and clinical 
outcomes of using ChartisTM to plan endobronchial valve treatment. Eur 
Respir J 2013;41(2):302–308.  
10.  Welling JBA, Hartman JE, Hacken NHT ten, et al. Chartis Measurement of 
Collateral Ventilation: Conscious Sedation versus General Anesthesia – A 
Retrospective Comparison. Respiration 2018;96(5):480–487.  
11.  Gompelmann D, Eberhardt R, Michaud G, Ernst A, Herth FJF. Predicting 
Atelectasis by Assessment of Collateral Ventilation prior to Endobronchial 
Lung Volume Reduction: A Feasibility Study. Respiration 2010;80(5):419–
425.  
12.  Slebos D-J, Shah PL, Herth FJF, Valipour A. Endobronchial Valves for 
Endoscopic Lung Volume Reduction: Best Practice Recommendations from 
Expert Panel on Endoscopic Lung Volume Reduction. Respiration 
2017;93(2):138–150.  
13.  Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol 
pharmacodynamics. Anesthesiology 1999;90(6):1502–16.  
14.  Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the 
pharmacokinetics and pharmacodynamics of remifentanil. I. Model 
development. Anesthesiology 1997;86(1):10–23.  
15.  Thiruvenkatarajan V, Maycock T, Grosser D, Currie J. Anaesthetic 
management for endobronchial valve insertion: lessons learned from a 





























Female/Male (%) 77/23 
Age (years) 62.8±5.7 
BMI (kg/m2) 23.9±3.9 
Pack-years (years) 49 (15-126) 
FEV1%predicted (%) 29 (21-56) 
RV%predicted (%) 227 (181-300) 
RV/TLC (ratio) 0.6 (0.6-0.8) 
pC02 in arterial blood gas (kPa) 5.3±0.6 
6MWD (meter) 369 (120-477) 
SGRQ total score (units) 54.7±11.0 
Data are presented as mean ± standard deviation in case of normal distribution 
of data and as median(range) in case of non-normal distribution. BMI: Body 
mass index; FEV1: forced expiratory volume in one second; RV: Residual volume; 












Difference  P-Value 
Measurement 
Duration of total Chartis procedure per patient (minutes) 20.3±4.2 15.1±4.4 5.2 [3.4-7.1] P<0.001 
Time until patient was sufficiently sedated to undergo Chartis 
measurement (minutes) 
12.5±3.0 7.6±1.8 4.9 [3.7-6.1] P<0.001 
Number of measurements per patient (number) 2 (1-3) 1 (1-3) 0 [0-0] P=1.00 
Success rate (%) 77% 97% NA P=0.07 
Feasibility 
Sum of feasibility scores (score) 12 (6-26) 7 (5-13) 6 [4-8] P<0.001 
Mucus (score) 4 (2-8) 3 (1-5) 2 [1-3] P<0.001 
Coughing (score) 4 (1-8) 1 (1-1) 3 [2-4] P<0.001 
Airway collapse (score) 2 (1-8) 1 (1-4) 1 [0-1] P=0.06 
Feasibility (score) 3 (1-7) 2 (1-4) 1 [1-2] P<0.01 




Propofol effect site concentration at time of start Chartis 
measurement (µg/ml) 
3 (1-5) 3 (2-5) -0.4 [-1-0.1] P=0.09 
Remifentanil effect site concentration at time of start Chartis 
measurement (ng/ml) 
1 (1-2) 4 (2-5) -3 [-3--3] P<0.001 
BIS score at time of start Chartis measurement (score)  76(46-88) 39 (24-64) 35[29-38] P<0.001 
Data are presented as mean ± standard deviation in case of normal distribution of data and as median (range) in case of 
non-normal distribution. The differences between the anesthesia methods are presented as mean or median [95% confidence 
interval]. Confidence intervals for non-normally distributed data were determined using Hodges Lehmann Estimator. 
Differences in outcomes between procedural sedation and general anesthesia were analyzed with a paired samples t-test in 
case of normal distribution of data or a Wilcoxon signed rank test in case of non-normal distribution of data. The difference in 
success rate of the measurements was analysed using a McNemar’s test. NA: Not applicable. BIS: Bispectral index. Mucus, 
coughing, airway collapse, feasibility and breathing instruction were scored on a 0 to 10 scale, with a score of 0 indicating, no 
mucus, no coughing, no airway collapse, very feasible measurement and no breathing instruction, and a score of 10 
indicating, large amounts of mucus, severe coughing, severe airway collapse, very unfeasible measurement and continuous 




Figure 1: Chartis measurement system 

